Clinic News Latest in CardiologyNoncigarette Tobacco Product Use Increases Subclinical Markers Related to CV HarmThe use of noncigarette tobacco products is associated with considerable cardiovascular risk, as demonstrated by relevant inflammation, thrombosis and atherosclerosis markers, according to a cross-sectional study published Jan. 27...ULTIMATE-DAPT: Ticagrelor Alone vs. Ticagrelor Plus Aspirin From Month 1 to Month 12 Post PCI in Patients With ACSThe ULTIMATE-DAPT (One-Month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes) trial data demonstrated that, in patients with acute coronary syndrome who underwent percutaneous coronary intervention and remained event-free after 1 month of dual antiplatelet therapy (DAPT), ticagrelor monotherapy (month 1 to month 12) resulted in lower bleeding events...ACCEL Lite: Implications for Ablation Outcomes: Results from the ARREST-AF TrialDrs. Marine and Pathak break down the key clinical takeaways and valuable insights on optimizing AFib management and improving outcomes through evidence-based strategies.Clinical Practice Algorithm For the Follow-Up of Repaired and Unrepaired Atrioventricular Septal DefectsApproximately 2,700 children (~5/10,000 live births) are born annually with atrioventricular septal defect (AVSD). AVSD represents a spectrum of congenital heart lesions that result from abnormal embryologic development of the endocardial cushions in the primitive atrioventricular (AV) canal.ACC CardiaCast: Conversations with Critical Care Cardiologists: Advanced Education and Training in CCCJoin us as we explore the future of CCC training, the role of medical societies, and strategies for ensuring consistency and excellence in education—both within CCC and across the broader field of cardiology.ACC Celebrates Heart Month 2025Join the ACC in celebrating Heart Month! Start off the month by reading the February issue of Cardiology magazine, including articles on health equity, life expectancy disparities in the U.S., polypharmacy for older adults and more.PURE: Secondary Prevention Medications For CVD Underused GloballySecondary prevention medications for cardiovascular diseases are underused globally and additional strategies to increase their use are needed to improve management and reduce premature mortality rates, according to results from the PURE study...Editors’ Corner | Steps in the Treatment of Pulmonary Embolism (Watch Out! The Staircase is Tricky!)Pulmonary embolism (PE) mortality has increased over the past decade and racial and geographic disparities persist. Black women and men have an approximately two-fold higher age-adjusted mortality rate compared with White women and men, respectively.Cover Story | Pulmonary Embolism: A Clinical ApproachPulmonary embolism (PE) continues to challenge clinicians with its complex presentation and potential for rapid deterioration. As the third leading cause of cardiovascular mortality in the U.S...Feature | Ten Americas: Growing Disparities Creating Demographic ChasmsRead the Health Equity Action Plan ACC's Diversity and Inclusion Hub, including the Heath Equity Resource Center Disparities in life expectancy, driven by race, geography, socioeconomic status and systemic inequities, have widened alarmingly – from a 12.6-year gap in 2000 to a staggering 20.4 years by 2021 in the U.S.1 This finding and more come […]
